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without clinically signiﬁcant GvHD, we previously identiﬁed a
panel of CML-associated antigens that are targets of antibodies
present in post-DLI sera. To gain insight into the possible mech-
anisms of immunogenicity of our GvL-associated target antigens,
we surveyed previously known cellular functions of our entire
panel of identiﬁed antigens, and observed that 70% are nucleic
acid binding proteins, thus predicting that sera from DLI respond-
ers may contain nucleic-acid containing activities that stimulate
immunity. Indeed, 5 of 6 post-DLI sera, but not pre-DLI sera,
induced a 3 to 50-fold increase in the expression of MIP-1alpha,
TNF-alpha, IP-10 and IFN-alpha transcripts in normal peripheral
blood mononuclear cells (PBMC). Cytokines were also not in-
duced by sera from 3 of 3 DLI non-responders or 3 of 3 CML
patients who achieved molecular remission after imatinib treat-
ment. This endogenous immunostimulatory factor required both
nucleic acid and protein for its adjuvant activity as pretreatment of
post-DLI sera with DNase, RNase, papain or pepsin resulted in
marked decrease in cytokine induction. To test for the role of
distinct TLRs in this response, HEK transfectants expressing
TLR3, 4, 8 or 9 were exposed to sera collected 6-12 months after
DLI. IL-8 expression increased only in the TLR8 and TLR9-
expressing cell lines that are known to be responsive to RNA and
DNA respectively. IL-8 expression was further induced by post-
DLI sera in TLR9-expressing cell lines co-transfected with CD32,
suggesting that internalization by FcR may enhance delivery of
nucleic acids to endosomal TLR8/9. None of the transfectants
could be activated by pre-DLI sera, nor by post-DLI sera from
non-responders. Finally, sera from responders collected as early as
2 weeks after DLI consistently activated TLR8 and 9 suggesting
that endogenous TLR8/9 activation may contribute to the early
immunologic events involved in effective DLI responses. Taken
together, these studies demonstrate for the ﬁrst time that effective
tumor immunity is correlated with the presence of endogenous
adjuvant-like nucleic-acid-immunoglobulin complexes in patient
sera. Ongoing studies are focused on studying the immunologic
effects of this endogenous adjuvant and determining which of our
previously identiﬁed CML antigens are bound to nucleic acids that
activate TLR8 and TLR9.
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CYTOTOXIC T LYMPHOCYTE RESPONSES TO PR1 PEPTIDE IN CML
PATIENTS INVERSELY CORRELATE WITH PROTEINASE 3 AND ELAS-
TASE EXPRESSION BUT DONOR PR1-RESPONSES DETERMINE MOLEC-
ULAR REMISSION AND DISEASE ERADICATION AFTER STEM CELL
TRANSPLANTATION
Yong, A.S.M.1, Rezvani, K.1, Savani, B.N.1, Eniafe, R.1, Mielke, S.1,
Goldman, J.M.1, Barrett, J.1 1NHLBI/NIH, Hematology Branch, 10
Center Drive, Bethesda, MD.
The primary granule proteins (PGP) neutrophil elastase (ELA2)
and proteinase 3 (PR3) both contain the nonapeptide PR1 which
can induce cytotoxic T lymphocyte (CTL) responses in chronic
myeloid leukemia (CML). The relative contribution of PR3 and
ELA2 to PR1 expression is not known. We previously found that
higher levels of PR3 and ELA2 gene expression in CD34 pro-
genitor cells were associated with longer survival in CML patients.
Eradication of leukemia requires elimination of leukemic stem
cells, which reside within the CD34 progenitor cell pool. We
therefore studied PGP expression and T cell response to PR1 in 31
CML patients and their HLA-identical family donors prior to
T-cell depleted allogeneic stem cell transplantation (SCT) with
T-cell add-back on day 45-100 post-SCT. CD8 T cells and
CD34 progenitor cells were puriﬁed from mononuclear cells
(MNC) of cryopreserved leukapheresis products from HLA-
A*0201 CML patients and their donors. ELA2 and PR3 gene
expression in MNC and CD34 cells was measured using real-
time quantitative polymerase chain reaction (RQ-PCR). To assess
PR1-CTL responses, T2 cells were loaded with PR1 peptide
(VLQELNVTV) and subsequently co-cultured with CD8 T
cells. PR1-CTL response was measured as interferon- mRNA
expression (relative to CD8) obtained by RQ-PCR. PR1-speciﬁc
CTL responses were detected in 7/28 CML patients and 7/27
HLA-identical donors. In CML patients, pre-SCT expression of
both PR3 and ELA2 in MNC was strongly correlated with the
expression in CD34 cells (p0.009 and p0.0006 respectively).
There was an inverse relationship between PR1-CTL response in
CML patients pre-SCT and PR3 or ELA2 expression (p0.02 and
p0.01 respectively). This data suggest that both PR3 and ELA2
expression in CD34 cells and their progeny are a potential source
of PR1. However, high expression of these proteins may result in
selective deletion of PR1 T cell clones. The presence of PR1-
responses in HLA-identical donors was associated with a signiﬁ-
cantly improved molecular remission rate from 3 months post-
SCT onwards, and moreover, was predictive of molecular
remission at 1-year post-SCT (p0.003). These ﬁndings support
peri-transplant vaccination strategies with PR1 peptide to eradicate
minimal residual disease. Conversely, in untransplanted patients,
the lower PR1 response in the presence of high PGP expression
suggests that vaccines given to patients with minimal residual
disease could result in tolerance to the leukemia.
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CD18 SEPARATES GVHD AND GVL EFFECT
Liang, Y.1, Anasetti, C.1, Yu, X.-Z.1 1H. Lee Mofﬁtt Cancer Center &
Research Institute, Tampa, FL.
Graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality in allogeneic hematopoietic stem cell
transplantation. Migration of donor-derived T cells into GVHD
target organs plays an essential role in the development of GVHD.
Beta2 integrins, a group of heterodimeric molecules including
CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), CD11c/CD18
and CD11d/CD18, are of critical importance for leukocyte extrav-
asation through vascular endothelia and for T cell activation. We
asked whether CD18-deﬁcient T cells would induce less GVHD
while sparing graft-versus-leukemia (GVL) effect. In murine allo-
geneic bone marrow transplantation (BMT) models, we found that
recipients of CD18-/- donor T cells had signiﬁcantly less GVHD
morbidity and mortality compared with recipients of WT donor T
cells. A cell-dose titration experiment indicated that the ability of
CD18-/- T cells had more than 4-fold reduction compared to that
of WT T cells in the induction of GVHD. Analysis of alloreactive
showed that CD18-/- and WT T cells had comparable activation,
expansion and cytokine production in vivo. Reduced GVHD was
associated with a signiﬁcant decrease in donor-T cell inﬁltration of
recipient intestine and with an overall decrease in pathologic scores
in intestine and liver. Finally, we found that in vivo GVL effect of
CD18-/- donor T cells was largely preserved, because mortality of
the recipients transplanted with CD18-/- T cells plus tumor cells
was greatly delayed or prevented. Our data suggest that strategies
to target beta2 intergrin have clinical potential to alleviate or
prevent GVHD while sparing GVL activity.
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INHIBITION OF HMG-COA REDUCTASE ACTIVITY WITH STATINS PRO-
VIDES ACUTE-GRAFT-VERSUS-HOST DISEASE PROTECTION BY TH-2
CYTOKINE INDUCTION WHILE SPARING GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Zeiser, R.1, Youssef, S.2, Baker, J.1, Steinman, L.2, Negrin, R.1 1Stan-
ford University Department of Medicine, Stanford, CA; 2Stanford Uni-
versity Department of Neurology, Stanford, CA.
The beneﬁcial impact of 3-hydroxy-3-methyl-CoA reductase in-
hibitors (statins) on autoimmunity and allograft rejection is well
documented. To investigate whether statins are capable of protect-
ing from acute graft vs host disease (aGVHD) we utilized an
established murine model (FVB/N into Balb/c). Type II statins
were potent inducers of a T-helper cell (Th)-2 cytokine proﬁle in
the adoptively transferred T cells upon exposure in vitro or in vivo.
Expansion of alloreactive luciferase transgenic T cells as measured
by total body light emission was signiﬁcantly reduced by donor
pre-treatment (10mg/kg) or in vitro T cell treatment (10nM) with
atorvastatin (AT vs PBS; p0.0008). The beneﬁcial effect of statin
treatment translated into signiﬁcantly reduced aGvHD lethality in
statin as compared to PBS treated animals. Th-2 biased donor T
cells could be tracked until day 25 after BMT. Host treatment
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prior to transplantation induced down-regulation of the costimu-
latory molecules CD40, CD80 and CD86 and MHC class II on
recipient APCs and enhanced the protective statin effect when
donor and recipient were treated (survival AT vs PBS, p0.0012).
Induction of the Th-2 cytokine proﬁle was still permissive for in
vivo graft vs leukemia effects by cytolytic effector function of
CD8 T cells against A20 B-cell lymphoma cells as assessed by
bioluminescence imaging, histology and survival. In vitro CD8 T
cells derived from AT treated animals displayed equal cytolytic
activity against Yac1 T-cell lymphoma cells as compared to T cells
derived from PBS treated animals. Mechanistically we identiﬁed a
role for the STAT-6 pathway in statin induced Th-2 induction as
aGvHD protection was partially reversed with STAT-6-/- donors.
Since L-mevalonate produced by the HMG-CoA reductase is the
precursor of non steroidal isoprenoid compounds, such as farnesyl
and geranylgeranyl pyrophosphate, the statin impact on prenyla-
tion status of critical signaling proteins in alloreactive T cells was
determined. In vitro AT treatment reduced the levels of RAP-1,
RhoB and Ras prenylation in allo-antigen exposed T cells and
abrogated expression of T-bet which is critical for Th1 induction.
We conclude that type II statins have signiﬁcant protective impact
on aGvHD lethality by Th-2 cytokine induction and inhibition of
an uncontrolled Th-1 response, without reduction of GvL activity
which is of great clinical relevance given the widespread use and
well deﬁned toxicity proﬁle of these agents.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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OUTCOMES OF DOUBLE CORD BLOOD TRANSPLANTATION (DCBT) IN A
DIVERSE POPULATION
Ballen, K.1, Nademanee, A.2, Graham, M.3, Jaing, T.-H.4, Tan, P.5,
Eames, G.6, Rosenthal, J.2, Karanes, C.2, Gjertson, D.7, Wang, B.8,
Petz, L.8, Chow, R.8,9,10 1Massachusetts General Hospital, Boston, MA;
2City of Hope National Medical Center, Duarte, CA; 3University of
Arizona Medical Center, Tucson, AZ; 4Chang Gung Children’s Hospital
& University, Linkou, Taiwan; 5Mount Elizabeth Hospital, Singapore;
6Cook Children’s Hospital, Fort Worth, TX; 7UCLA School of Public
Health, Los Angeles, CA; 8StemCyte International Cord Blood Center,
Arcadia, CA; 9StemCyte Taiwan National Cord Blood Center, Linkou,
Taiwan; 10StemCyte Research Institute, Arcadia, CA.
Cord blood is an alternative stem cell source for patients, but
single cord blood units (CBU) may not contain sufﬁcient cell dose
for cord blood transplantation of adults. Double cord blood trans-
plantation (DCBT) has been used to increase the cell dose, but the
majority of reported patients have been Caucasian. We conducted
a retrospective analysis of 43 consecutive DCBT recipients who
received at least one cord blood unit from the StemCyte cord
blood banks. The median age was 21 years (range 1-59) and the
median weight was 59 kg (range 11-112). Diagnoses were: 14
AML, 9 ALL, 6 CML, 5 Thalassemia, 2 Myelodysplasia, 1 lym-
phoma, 1 aplastic anemia and 5 others. 54% were advanced risk,
26% standard risk, and 20% unknown risk status for the leukemia/
lymphoma/MDS cases. Sixty seven percent of the recipients were
non-Caucasian&em;15 patients were Asian, 14 Caucasian, 4 Native
American, 3 Hispanic, 3 African American, 1 mixed race and 3
unknown. Patients were treated with a variety of conditioning
regimens (28% reduced intensity) at 21 international centers over
4 continents. 19 patients received 2 plasma depleted cord blood
units. Cord unit characteristics were as follows: median pre-freeze
TNC dose 3.4  107/kg, median pre-freeze CD34 dose 1.1 
105/kg. The median time to neutrophil (ANC500) engraftment
was 22 days and the median time to platelet 20K and 50K engraft-
ment were 45 days and 62 days respectively. Kaplan-Meier esti-
mates of 1-year transplant related mortality, overall survival, and
disease free survival were 37%, 49%, and 44 % respectively.
Causes of death include infection (33%), multi-organ failure
(21%), relapse (17%), GvHD (0%), and other (29%). Engraftment
correlated with cell dose and disease risk status in univariate anal-
ysis. In conclusion, 1) Double cord blood transplantation can be
performed effectively in a racially diverse patient population, 2)
Plasma depleted cord blood units can be used safely, 3) Cell counts
remain important for engraftment even with the use of 2 cord
blood units.
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION WITH RE-
DUCED INTENSITY CONDITIONING AND SIROLIMUS-BASED GVHD
PROPHYLAXIS
Cutler, C.1, Haspel, R.2, Kao, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1,
Dey, B.2, Spitzer, T.2, Soiffer, R.J.1, Antin, J.H.1, Ballen, K.1 1Dana-
Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital,
Boston, MA.
Umbilical cord blood (UCB) is an alternative for patients without
related or unrelated donors. Single-unit UCB transplantation in
adults is associated with high transplant related mortality, largely due
to delayed engraftment and infection, so we studied the value of
double unit umbilical cord blood (DUCB) transplantation.Methods:
Reduced-intensity conditioning consisted of ﬂudarabine 30mg/m2 x 6
days, melphalan 100mg/m2 x 1 day, and rabbit ATG 1.5 mg/kg x 4
days. DUCB units were 4/6 HLA-A, B, DR1 matched with each
other and the recipient, and contained a minimum combined dose of
3.7  107 TNC/kg (pre-cryopreservation). GVHD prophylaxis con-
sisted of tacrolimus (serum conc. 5-10 ng/ml) and sirolimus (serum
conc. 3-12 ng/ml), which is effective in PBSC transplantation. Re-
sults: 18 patients (median age 48.5 years, range 19-64) with100 day
follow-up are reported. Diagnoses include NHL(6), AML(5),
MDS(3), HD(3), and CML(1). The total cell doses infused were
4.23 107 TNC/kg (range 3.51–6.74 107) and 2.11 105 CD34
cells/kg (range 0.48–5.67 105). Subjects engrafted neutrophils at 22
(median, range 15–75) and platelets at 46 (median, range 24-69) days
from transplantation. Two subjects did not attain platelet transfusion
independence and there was 1 late graft failure. 100-day treatment-
related mortality was 16.7%. 3 patients developed Gr II-IV acute
GVHD (2 Gr. II and 1 Gr. III) and 2 patients developed chronic
GVHD at a median of 30 and 203 days from transplantation respec-
tively. The median follow up is 6.5 months (range 3-12 months) and
overall survival at 1 year is 64.3%. Causes of death include sepsis(4),
relapse(1), and EBV-associated PTLD(1). Chimerism analysis (n14)
at day 30 revealed complete single cord chimerism in 3, mixed cord
chimerism in 10, and persistent host hematopoiesis with single or
double cord chimerism in 1. By day 100, 5/9 patients demonstrated
complete single cord chimerism and 3/9 demonstrated persistent
double cord chimerism. Conclusions: This study demonstrates ex-
cellent engraftment after DUCB transplantation in adult recipients
after a reduced-intensity conditioning regimen. Using sirolimus and
tacrolimus as GVHD prophylaxis, the risk of acute and chronic
GVHD is low when compared to our prior experience with cyclo-
sporine and MMF, and survival is comparable to other unrelated
donor cohorts. Long-term follow-up on an expanded patient cohort
will be presented at ASBMT.
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EFFECT OF CD3 CELL DOSE ON OUTCOME IN PATIENTS AFTER
CONDITIONING INCLUDING ANTITHYMOCYTE GLOBULIN FOLLOWED
BY UN-MANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD
AND MARROW TRANSPLANTATION
Dong, L.1,2, Wu, T.1,2, Lu, D.-P.1,2, Zhang, M.-J.3, Chen, H.1,2,
Gao, Z.-Y.1,2, Han, W.1, Zhang, Y.-C.1,2, Wang, J.-B.2, Liu, Y.-R.1
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